FAS and neoplasm: A study that compared tumor gene mutations and biomarker immune expression between races found that Black patients had significantly higher KRAS mutation rates for valine and lower KRAS mutation rates for cysteine; Fas expression was also lower in Black patients, while the immune expression of HER2 tended to be elevated (29, 30).